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INTRODUCTION 
A gastroretentive dosage form will release the drug over an 
extended period in the stomach and upper gastrointestinal 
tract (GIT) thus enhancing the opportunity for absorption. 
Various approaches have been proposed to control the 
gastric residence of drug delivery systems in the upper part 
of the GIT including floating drug delivery systems 
(FDDS)1,2 high density DDS, mucoadhesive systems3-5, 
swelling and expanding DDS6, modified shape systems7 
and other delayed gastric devices8. FDDS is a 
gastroretentive dosage form (GRDF), which can prolong 
the gastric residence time (GRT) to produce an acceptable 
drug bioavailability9, 10. FDDS is suitable for drugs with an 
absorption window in the stomach or the upper small 
intestine 11, for drugs which act locally in the stomach 12 
and for drugs that are poorly soluble or unstable in the 
intestinal fluid. 
Normal gastric residence times usually range between 5 
minutes and 2 hours. Migrating myoelectric complex 
(MMC) is characterized by four phases: Phase I–Period of 
no contraction (40-60 minutes), phase II –Period of 
intermittent contractions (20-40 minutes), phase III– 
Period of regular contractions at the maximal frequency 
that travel distally also known as housekeeper wave. (10- 
20 minutes) and phase IV Period of transition between 
phase III and phase I (0-5 minutes) 13. 
FLOATING DRUG DELIVERY SYSTEM: 
Floating systems or Hydrodynamically controlled systems 
are low-density systems that have sufficient buoyancy to 
float over the gastric contents and remain buoyant in the  
 
stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on 
the gastric contents, the drug is released slowly at the 
desired rate from the system. After release of drug, the 
residual system is emptied from the stomach 14. This 
results in an increased GRT and a better control of the 
fluctuations in plasma drug concentration. However, 
besides a minimal gastric content needed to allow the 
proper achievement of the buoyancy retention principle, a 
minimal level of floating force (F) is also required to keep 
the dosage form reliably buoyant on the surface of the 
meal. Many buoyant systems have been developed based 
on granules, powders, capsules, tablets, laminated films 
and hollow microspheres 15.  
CLASSIFICATION OF FLOATING DRUG 
DELIVERY SYSTEM
 16
: 
Floating drug delivery systems are classified depending on 
the use of two formulation variables: effervescent and non-
effervescent systems. 
Effervescent Floating Dosage Forms: 
These are matrix types of systems prepared with the help 
of swellable polymers such as methylcellulose and 
chitosan and various effervescent compounds, eg, sodium 
bicarbonate, tartaric acid, and citric acid. They are 
formulated in such a way that when in contact with the 
acidic gastric contents, C02 is liberate and gas entrapped in 
swollen hydrocolloids which provides buoyancy to the 
dosage forms. 
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Non-effervescent Floating Dosage 
Forms: 
Non-effervescent floating dosage 
forms use a gel forming or swellable 
cellulose type hydrocolloids, 
polysaccharides, and matrix-forming 
polymers like polycarbonate, 
polyacrylate, polymethacrylate, and 
polystyrene. The formulation method 
includes a simple approach of 
thoroughly mixing the drug and the 
gel-forming hydrocolloid. After oral 
administration this dosage form swells 
in contact with gastric fluids and 
attains a bulk density of < 1. The air 
entrapped within the swollen matrix 
imparts buoyancy to the dosage form. 
The so formed swollen gel-like 
structure acts as a reservoir and allows 
sustained release of drug through the 
gelatinous mass. 
 
                   Figure 1: Different approaches of gastric retention 
 
BIOADHESIVES SYSTEMS: 
Another approach to increase gastric residence time of the 
dosage forms is to bind them to gastric mucosa or epithelial 
cell surfaces. Scientists studied a broad spectrum of 
polymers for their bioadhesive properties17. They concluded 
that anionic polymers have better binding capacity than 
neutral or cationic polymers. In case of bioadhesive 
systems, the mechanism of adhesion is thought to be the 
formation of electrostatic and hydrogen bonding at the 
mucus-polymer boundary. The adhesion is favored by rapid 
hydration. These bioadhesive systems do not seem to be a 
very feasible solution as this bond formation is prevented by 
the acidic environment and thick mucus present in the 
stomach18. High turnover of mucus adds to the difficulties in 
retaining a bioadhesive system at the site. 
Mucoadhesive tablets, in general, have the potential to be 
used for controlled release drug delivery, but coupling of 
mucoadhesive properties to tablet has additional advantages, 
e.g. efficient absorption and enhanced bioavailability of the 
drugs due to a high surface to volume ratio, a much more 
intimate contact with the mucus layer. Mucoadhesive tablets 
can be tailored to adhere to any mucosal tissue including 
those found in stomach19, thus offering the possibilities of 
localized as well as systemic controlled release of drugs. 
The application of mucoadhesive tablets to the mucosal 
tissues of gastric epithelium is used for administration of 
drugs for localized action. Mucoadhesive tablets are widely 
used because they release the drug for prolong period, 
reduce frequency of drug administration and improve the 
patient compliance. 
ADVANTAGES OF GASTRORETENTION SYSTEM
 
20, 21
: 
1. The gastroretensive systems are advantageous for drugs 
meant for local action in the stomach. e.g. antacids. 
2. Acidic substances like aspirin cause irritation on the 
stomach wall when come in contact with it. Hence HBS 
formulation may be useful for the administration of 
aspirin and other similar drugs. 
3. When there is a vigorous intestinal movement and a 
short transit time as might occur in certain type of 
diarrhea, poor absorption is expected. Under such 
circumstances it may be advantageous to keep the drug 
in floating condition in stomach to get a relatively better 
response. 
4. The gastroretensive systems are advantageous for drugs 
absorbed through the stomach. e.g. Ferrous salts, 
antacids. 
DISADVANTAGES OF GASTRORETENTION 
SYSTEM
22
: 
Such systems cannot be used in the case of drugs like 
aspirin and other nonsteroidal anti-inflammatory drugs like 
aspirin and other nonsteroidal anti-inflammatory drugs that 
induce gastric lesions or for drugs that are unstable in the 
acidic environment of stomach.  
Many times it is difficult to incorporate a drug in such 
gastric retention systems. The retention of these systems 
depends on many factors such as gastric motility, pH, and 
presence of food. It is not easy to design and fabricate a 
system that can overcome all these difficulties. 
BILAYER AND FLOATING- BIOADHESIVE DRUG 
DELIVERY SYSTEMS: 
Various approaches have been worked out to improve the 
retention of oral dosage form in the stomach, e.g. floating 
systems, swelling and expanding systems, bioadhesive 
systems, high density systems. Floating systems are low-
density systems that have sufficient buoyancy to float over 
the gastric contents and remain in the stomach for a 
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prolonged period. While the system floats over the gastric 
contents, the drug is released slowly at the desired rate, 
which results in increased gastro-retention time and reduces 
fluctuation in plasma drug concentration, Bioadhesive 
delivery systems are capable to adhere to mucous membrane 
that prevents their passage through the pylorus; as a result, 
the dosage form is retained in the stomach for a longer 
period of time.  
In this article, an effervescent floating system and a 
bioadhesion system will be in combination. Floating dosage 
forms are meant to remain floating on the gastric fluid when 
the stomach is full after a meal. However, as the stomach 
empties and the tablet reaches the pylorus, the buoyancy of 
the dosage form may be reduced. It may be that the dosage 
form will then pass through the pylorus into the small 
intestine. Thus, the buoyancy of an FDDS in the stomach 
may be limited to only 3–4 h. Furthermore, floating systems 
do not always release the drug at the intended site. In a 
bioadhesive drug delivery system, it is quite likely that the 
system becomes dislodged from the stomach mucosa wall 
when the system is full and the semi-liquid contents are 
churning around due to the effect of peristalsis23. A floating-
bioadhesive system would overcome these drawbacks of 
floating and bioadhesive systems and would have a 
significant effect on improving the therapeutic effect of the 
drug involved24. The purpose of this paper is to develop a 
novel sustained release tablet with a unique combination of 
bioadhesion and floatation to prolong the gastric residence 
time of active pharmaceutical ingredients (API), which is 
absorbed from the gastrointestinal tract while its solubility 
decreases with increasing pH over the physiological range. 
Bilayer tablets have some key advantages compared to 
conventional monolayer tablets. For instance, such tablets 
are commonly used to avoid chemical incompatibilities of 
formulation components by physical separation. In addition, 
bilayer tablets have enabled the development of controlled 
delivery of active pharmaceutical ingredients with pre-
determined release profiles by combining layers with 
various release patterns, or by combining slow-release with 
immediate-release layers. 
NEED OF BILAYER TABLETS
 25, 26
: 
1. For the administration of fixed dose combinations of 
different APIs 13, prolong the drug product life cycle, 
buccal/ mucoadhesive delivery systems 15, fabricate 
novel drug delivery systems such as chewing device 
and floating tablets for gastro-retentive drug delivery. 
2. Controlling the delivery rate of either single or two 
different active pharmaceutical ingredient(s)  
3. To modify the total surface area available for API 
layer either by sandwiching with one or two inactive 
layers in order to achieve swellable/erodible barriers 
for modified release. 
4. To separate incompatible Active pharmaceutical 
ingredient (APIs) from each other, to control the 
release of API from one layer by utilizing the 
functional property of the other layer (such as, osmotic 
property).  
ADVANTAGES OF THE BI-LAYER TABLET 
DOSAGE FORM: 
1. Bi-Layer execution with optional single-layer 
conversion kit. 
2. Cost is lower compared to all other oral dosage form.  
3. Greatest chemical and microbial stability over all oral 
dosage form.  
4. Objectionable odor and bitter taste can be masked by 
coating technique.  
5. Flexible Concept. 
6. They are unit dosage form and offer the greatest 
capabilities of all oral dosage form for the greatest 
dose precision and the least content variability.  
7. Easy to swallowing with least tendency for hang-up. 
8. Suitable for large scale production.  
DISADVANTAGES OF BI-LAYER TABLET DOSAGE 
FORM ARE: 
1. Some drugs resist compression into dense compacts, 
owing to amorphous nature, low density character. 
2. Bitter testing drugs, drugs with an objectionable odor 
or drugs that are sensitive to oxygen may require 
encapsulation or coating.  
3. Difficult to swallow in case of children and 
unconscious patients.  
4. Drugs with poor wetting, slow dissolution properties, 
optimum absorption high in GIT may be difficult to 
formulate or manufacture as a tablet that will still 
provide adequate or full drug bioavailability.  
CONCLUSION: 
Bilayer and floating-bioadhesive dosage forms exhibit a 
unique combination of floatation and adhesion for 
prolonged residence in the stomach. Bi-layer tablets provide 
one of the important design approaches where incompatible 
drugs, with different indication, and same drug with 
different release rate (e.g. IR and ER) can be incorporated in 
a single unit. Many different types of presses are being used 
to produce bi-layer tablets, ranging from simple single-sided 
presses to highly sophisticated machines such as the 
Courtoy-R292F. The preparation of tablets in the form of bi- 
layers is used to provide systems for the administration of 
drugs, which are incompatible and to provide controlled 
release tablet preparations by providing surrounding or 
multiple swelling layers. 
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